Companies: 10,795·Total market cap: $144.5T
Landos Biopharma, Inc.

Landos Biopharma, Inc.

LABPNASDAQHealthcare
$22.93
+$0.13(+0.57%)
Market Cap$71675511
P/E Ratio
52W High$22.94
52W Low$3.145
Overview

Landos Biopharma, Inc. (LABP) · Income Statement

Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.

FMP · LABP · as of 2026-06-09

Financial statements

Revenue · Gross Profit · Net Income
Breakdown2023-122022-122021-122020-122019-12
Revenue
Revenue$0.00B$0.00B$0.02B$0.00B$0.00B
Cost of Revenue$0.00B$0.00B$0.00B$0.00B$0.00B
Gross Profit$0.00B($0.00B)$0.02B($0.00B)($0.00B)
Gross Margin %(computed)98.91%
Operating Expenses
R&D Expenses$0.01B$0.03B$0.04B$0.03B$0.01B
G&A Expenses$0.01B$0.01B$0.02B$0.01B$0.00B
Total Operating Expenses$0.02B$0.04B$0.06B$0.03B$0.01B
Operating Income($0.02B)($0.04B)($0.04B)($0.03B)($0.01B)
Operating Margin %(computed)-215.64%
Interest Income$0.00B$0.00B$0.00B$0.00B$0.00B
Interest Expense$0.00B$0.00B$0.00B$0.00B$0.00B
Income Before Tax($0.02B)($0.04B)($0.04B)($0.03B)($0.01B)
Income Tax Expense$0.00B($0.00B)($0.00B)$0.00B$0.00B
Net Income($0.02B)($0.04B)($0.04B)($0.03B)($0.01B)
Net Margin %(computed)-212.37%
Per Share & EBITDA
EPS (Basic)$-3.50$-9.44$-9.50$-7.51$-3.47
Wtd Avg Shares0.01B0.00B0.00B0.00B0.00B
EBITDA($0.02B)($0.04B)($0.04B)($0.03B)($0.01B)
EBITDA Margin %(computed)-214.56%

Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B

Explore more Landos Biopharma, Inc. data

About Landos Biopharma, Inc. (LABP) Income Statement

Landos Biopharma, Inc. (LABP) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, LABP reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.02B) — a net profit margin of —.

Frequently asked questions

LABP · 4 questions

Landos Biopharma, Inc. (LABP) reported revenue of $0.00B for 2023, down —% year-over-year.

LABP revenueLABP salesannual revenue YoYincome statement

· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09